KalVista Pharmaceuticals Acquired by Chiesi Group | Healthcare M&A Deal

Chiesi Group has acquired KalVista Pharmaceuticals, a pharmacy business in Parma, Italy, for $1.9 billion. Chiesi Group acquisitions focus on rare disease therapeutics, and the KalVista Pharmaceuticals acquisition adds EKTERLY (sebetralstat), an oral, on-demand plasma kallikrein inhibitor for hereditary angioedema attacks in adults and adolescents aged 12 and older. The therapy is approved across the US, UK, EU, and Japan, and Chiesi Group plans further regulatory expansion, including a planned US filing for children aged 2 to 11. The strategic acquisition is structured as a platform acquisition in healthcare M&A, with unanimous board approval and an expected close in Q3 2026 at $27.00 per share in cash.